NYSE:ABBVBiotechs
AbbVie Cancer Updates Highlight Epcoritamab Data And RC148 Deal For Investors
AbbVie (NYSE:ABBV) reported positive Phase 3 EPCORE DLBCL-1 results for epcoritamab as a monotherapy in relapsed or refractory diffuse large B-cell lymphoma.
The Phase 3 data showed improvement in progression-free survival for patients with limited treatment options.
AbbVie also entered an exclusive licensing agreement with RemeGen for RC148, a first in class PD-1/VEGF-targeted bispecific antibody for solid tumors.
AbbVie is a large biopharmaceutical company with a significant focus on...